Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda.

Nunn A, Anywaine Z, Seeley J, Munderi P, Levin J, Kasirye R, Kamali A, Abaasa A, Grosskurth H.

Contemp Clin Trials Commun. 2016 Aug 15;3:142-146.

2.

Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.

Kasirye R, Grosskurth H, Munderi P, Levin J, Anywaine Z, Nunn A, Kamali A, Baisley K.

Malar J. 2016 Jul 15;15:361. doi: 10.1186/s12936-016-1426-z.

3.

Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.

Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulsom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team.

J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.

4.

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.

Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M; Host-Directed Therapies Network consortium.

Lancet Infect Dis. 2016 Apr;16(4):e47-63. doi: 10.1016/S1473-3099(16)00078-5. Review.

PMID:
27036359
5.

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.

Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team.

BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.

6.

Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda.

Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T, Kapaata AA, Nanyonga F, Parry CM, Magambo B, Nazziwa J, Nannyonjo M, Hughes P, Hladik W, Ruberantwari A, Namuwenge N, Musinguzi J, Downing R, Katongole-Mbidde E; HIV Drug Resistance Working group.

PLoS One. 2015 Dec 23;10(12):e0145536. doi: 10.1371/journal.pone.0145536. eCollection 2015.

7.

Feasibility and acceptability of mobile phone short message service as a support for patients receiving antiretroviral therapy in rural Uganda: a cross-sectional study.

Kim J, Zhang W, Nyonyitono M, Lourenco L, Nanfuka M, Okoboi S, Birungi J, Lester RT, Kaleebu P, Munderi P, Moore DM.

J Int AIDS Soc. 2015 Dec 10;18:20311. doi: 10.7448/IAS.18.1.20311. eCollection 2015.

8.

Community-based ART distribution system can effectively facilitate long-term program retention and low-rates of death and virologic failure in rural Uganda.

Okoboi S, Ding E, Persuad S, Wangisi J, Birungi J, Shurgold S, Kato D, Nyonyintono M, Egessa A, Bakanda C, Munderi P, Kaleebu P, Moore DM.

AIDS Res Ther. 2015 Nov 12;12:37. doi: 10.1186/s12981-015-0077-4. eCollection 2015.

9.

Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.

Kasirye RP, Baisley K, Munderi P, Levin J, Anywaine Z, Nunn A, Kamali A, Grosskurth H.

AIDS. 2016 Feb 20;30(4):635-44. doi: 10.1097/QAD.0000000000000956.

10.

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.

Ford D, Robins JM, Petersen ML, Gibb DM, Gilks CF, Mugyenyi P, Grosskurth H, Hakim J, Katabira E, Babiker AG, Walker AS; DART Trial Team.

Am J Epidemiol. 2015 Oct 1;182(7):633-43. doi: 10.1093/aje/kwv083. Epub 2015 Aug 26.

11.

Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.

Zumla A, Maeurer M; Host-Directed Therapies Network (HDT-NET) Consortium.

Clin Infect Dis. 2015 Nov 1;61(9):1432-8. doi: 10.1093/cid/civ631. Epub 2015 Jul 28.

PMID:
26219693
12.

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.

Musoke P, Szubert AJ, Musiime V, Nathoo K, Nahirya-Ntege P, Mutasa K, Williams DE, Prendergast AJ, Spyer M, Walker AS, Gibb DM; ARROW Trial Team.

AIDS. 2015 Aug 24;29(13):1623-32. doi: 10.1097/QAD.0000000000000749.

13.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

14.

Towards host-directed therapies for tuberculosis.

Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS.

Nat Rev Drug Discov. 2015 Aug;14(8):511-2. doi: 10.1038/nrd4696. Epub 2015 Jul 17.

PMID:
26184493
15.

Readiness of Ugandan health services for the management of outpatients with chronic diseases.

Katende D, Mutungi G, Baisley K, Biraro S, Ikoona E, Peck R, Smeeth L, Hayes R, Munderi P, Grosskurth H.

Trop Med Int Health. 2015 Oct;20(10):1385-95. doi: 10.1111/tmi.12560. Epub 2015 Jul 8.

16.

High prevalence of hypertension and of risk factors for non-communicable diseases (NCDs): a population based cross-sectional survey of NCDS and HIV infection in Northwestern Tanzania and Southern Uganda.

Kavishe B, Biraro S, Baisley K, Vanobberghen F, Kapiga S, Munderi P, Smeeth L, Peck R, Mghamba J, Mutungi G, Ikoona E, Levin J, Bou Monclús MA, Katende D, Kisanga E, Hayes R, Grosskurth H.

BMC Med. 2015 May 29;13:126. doi: 10.1186/s12916-015-0357-9.

17.

Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.

Anywaine Z, Abaasa A, Levin J, Kasirye R, Kamali A, Grosskurth H, Munderi P, Nunn A.

Contemp Clin Trials. 2015 Jul;43:100-4. doi: 10.1016/j.cct.2015.05.015. Epub 2015 May 22.

18.

Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Baker JV, Engen NW, Huppler Hullsiek K, Stephan C, Jain MK, Munderi P, Pett S, Duprez D; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:109-18. doi: 10.1111/hiv.12239.

19.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.

HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.

20.

The health system burden of chronic disease care: an estimation of provider costs of selected chronic diseases in Uganda.

Settumba SN, Sweeney S, Seeley J, Biraro S, Mutungi G, Munderi P, Grosskurth H, Vassall A.

Trop Med Int Health. 2015 Jun;20(6):781-90. doi: 10.1111/tmi.12487. Epub 2015 Mar 6.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk